EBAG9/RCAS1 Antibody (CPTC-EBAG9-2) [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-08860B
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry-Paraffin, Western Blot
Label
Biotin
Antibody Source
Monoclonal Mouse IgG2a Kappa Clone # CPTC-EBAG9-2
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant full-length human EBAG9/RCAS1 protein (Uniprot: O00559)
Localization
Golgi apparatus
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2a Kappa
Applications for EBAG9/RCAS1 Antibody (CPTC-EBAG9-2) [Biotin]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: EBAG9/RCAS1
Alternate Names
Cancer-associated surface antigen RCAS1, EB9cancer associated surface antigen, estrogen receptor binding site associated, antigen, 9, Estrogen receptor-binding fragment-associated gene 9 protein, RCAS1PDAF, receptor-binding cancer antigen expressed on SiSo cells
Gene Symbol
EBAG9
Additional EBAG9/RCAS1 Products
Product Documents for EBAG9/RCAS1 Antibody (CPTC-EBAG9-2) [Biotin]
Product Specific Notices for EBAG9/RCAS1 Antibody (CPTC-EBAG9-2) [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...